Back to news
Daily Market Briefing · 16 November 2026

EMA Committee Backs Seven New Medicines and Adds a Contraception Warning for Tirzepatide

The November regulatory package spans cancer, hypertension, insulin competition and HIV prevention, but every positive opinion still awaits the next formal step.

Seven positive opinions are not yet final approvals

The European Medicines Agency’s human medicines committee recommended seven new medicines after its November 9–12 meeting. They include Aumseqa for non-small-cell lung cancer, AstraZeneca’s Baxfendy for insufficiently controlled hypertension and Zybrivo for non-squamous lung cancer. Two insulin-aspart biosimilars and two generics also received positive opinions. The European Commission must still issue marketing-authorisation decisions, so the recommendations should not be described as completed commercial launches.[1]

Competition enters established treatment classes

The two proposed insulin-aspart biosimilars, Garzulys and Donrafylix, would treat patients from one year of age. The generics cover fondaparinux, used for clot prevention and treatment, and ruxolitinib for several blood disorders and graft-versus-host disease. If authorised and launched, these products could broaden supplier choice in mature medicine categories. Actual price effects will depend on procurement, national substitution rules, manufacturing capacity and the applicants’ launch decisions, none of which the committee opinion resolves.[1]

Longer HIV-prevention ring and broader indications

For use outside the EU, the committee supported a 100-milligram dapivirine vaginal ring intended to reduce sexual acquisition of HIV-1 in women aged 16 and older. The higher strength permits replacement every three months rather than monthly. Experts from WHO and regulators in Kenya, South Africa and Zambia participated. The committee also recommended 11 indication extensions, including obinutuzumab for systemic lupus erythematosus and osilodrostat for endogenous Cushing syndrome in children from six years of age.[1]

Tirzepatide communication addresses limited evidence

The committee adopted a professional communication concerning the possible effect of Mounjaro, or tirzepatide, on oral contraceptive reliability. Because information remains limited, users of oral contraception are advised to add a barrier method for four weeks after starting treatment and after each dose increase, or to switch to a non-oral method. This is a precautionary risk-management step, not evidence that every oral contraceptive fails. The communication will be distributed after a European Commission decision.[1]

Sources & evidence

  1. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026 (opens in a new tab)
    European Medicines AgencySource language en

    All regulatory recommendations, pending status, indication extensions, dapivirine assessment and tirzepatide communication.

    Source note

    Full public regulator release; minutes were still pending.